Evaluation of Subcutaneous Rituximab Administration on Canadian Systemic Therapy Suites
نویسندگان
چکیده
منابع مشابه
A Canadian perspective on the subcutaneous administration of rituximab in non-Hodgkin lymphoma.
Rituximab is widely used for the treatment of non-Hodgkin lymphoma, being a key component in most therapeutic regimens. Administration of the intravenous (IV) formulation is lengthy and places a significant burden on health care resources and patient quality of life. A subcutaneous (sc) formulation that provides a fixed dose of rituximab is being examined in a number of studies. Results indicat...
متن کاملEvaluation of a novel autoinjector for subcutaneous self-administration of belimumab in systemic lupus erythematosus
OBJECTIVE To study self-administration and pharmacokinetics (PK) of subcutaneous (SC) belimumab in patients with systemic lupus erythematosus (SLE). METHODS Patients previously treated with belimumab self-administered belimumab 200 mg SC weekly for 8 weeks using an autoinjector. The primary endpoint was the proportion of patients able to self-administer their first and second dose (weeks 1 an...
متن کاملRituximab therapy for refractory systemic-onset juvenile idiopathic arthritis.
Systemic-onset juvenile idiopathic arthritis (SOJIA), formerly called Still’s disease, is a subset of juvenile arthritis that describes patients with fever, rash, arthritis, serositis and visceromegaly. In up to 30% of cases the disease has a chronic course and management requires high doses of glucocorticoids, disease-modifying antirheumatic drugs (DMARD), tumour necrosis factor alpha (TNFa) i...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Current Oncology
سال: 2018
ISSN: 1718-7729
DOI: 10.3747/co.25.4231